5.7 C
New York
Thursday, April 25, 2024
HomeMarkets
Markets

Benzinga's Top #PreMarket Gainers

By Insider Scoop
0
58
psw-placeholder
psw-placeholder

Courtesy of Benzinga.

Related XOMA
UPDATE: XOMA Announces Development and Commercialization Agreement
10% Annual Alpha? Why Pair Trades Make Sense When The Market Is Volatile

Related
US Stock Futures Gain Ahead Of Economic Data
Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy
Sarepta on losing end of exon 51 skipping patent ruling in favor of BioMarin, plans to appeal (Seeking Alpha)

XOMA Corp (NASDAQ: XOMA) gained 71.61 percent to $1.290 in pre-market trading after the company reported a development and commercialization agreement for first-in-class anti-TGF-beta antibody program in immuno-oncology.

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares rose 14.61 percent to $36.80 in pre-market trading on positive eteplirsen data.

Synergy Pharmaceuticals Inc (NASDAQ: SGYP) shares rose 7.01 percent to $5.65 in pre-market trading. H.C. Wainwright initiated coverage on Synergy Pharmaceuticals with a Buy rating and a $20.00 price target.

Novavax, Inc. (NASDAQ: NVAX) shares climbed 4.52 percent to $7.40 in pre-market trading after surging 10.45 percent on Wednesday.

Linn Energy LLC (NASDAQ: LINE) shares rose 4.46 percent to $2.81 in pre-market trading after gaining 5.08 percent on Wednesday.

Posted-In: PreMarket GainersNews Pre-Market Outlook Markets Movers

Subscribe
Notify of
0 Comments
Inline Feedbacks
View all comments

Stay Connected

157,325FansLike
396,312FollowersFollow
2,290SubscribersSubscribe

Latest Articles

Load more

Note: The material presented in this commentary is provided for informational purposes only and is based upon information that is considered to be reliable. However, neither PSW Investments, LLC d/b/a PhilStockWorld (PSW) nor its affiliates warrant its completeness, accuracy or adequacy and it should not be relied upon as such. Neither PSW nor its affiliates are responsible for any errors or omissions or for results obtained from the use of this information. Past performance, including the tracking of virtual trades and portfolios for educational purposes, is not necessarily indicative of future results. Neither Phil, Optrader, or anyone related to PSW is a registered financial adviser and they may hold positions in the stocks mentioned, which may change at any time without notice. Do not buy or sell based on anything that is written here, the risk of loss in trading is great.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities or other financial instruments mentioned in this material are not suitable for all investors. Any opinions expressed herein are given in good faith, are subject to change without notice, and are only intended at the moment of their issue as conditions quickly change. The information contained herein does not constitute advice on the tax consequences of making any particular investment decision. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation to you of any particular securities, financial instruments or strategies. Before investing, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.

Contact us: support@philstockworld.com

© Copyright - PSW, LLC.

2024
0
Would love your thoughts, please comment.x
()
x